[Are leukemic patient bone marrow mesenchymal stem cells malignant?].

Area of Science:

• Hematology
• Stem Cell Biology
• Oncology

Background:

• Mesenchymal stem cells (MSCs) are crucial for bone marrow microenvironment regulation.
• Leukemia disrupts the bone marrow niche, raising questions about MSC normality.
• Investigating MSCs from leukemia patients is vital for understanding disease mechanisms and therapeutic potential.

Purpose of the Study:

• To determine if bone marrow mesenchymal stem cells (BMMSC) from leukemia patients exhibit leukemic characteristics.
• To compare the biological properties of BMMSC from leukemia patients versus healthy controls.
• To assess the potential of leukemia-derived BMMSC for therapeutic applications.

Main Methods:

• Isolation and in vitro culture of BMMSC from normal volunteers and patients with Acute Promyelocytic Leukemia (APL) and Chronic Myeloid Leukemia (CML).
• Assessment of morphology, growth curves, and cell surface markers of isolated BMMSC.
• Fluorescent in situ hybridization (FISH) to detect leukemia-specific abnormal fusion genes in BMMSC.

Main Results:

• No significant morphological or growth differences were observed between BMMSC from leukemia patients and healthy controls.
• BMMSC derived from leukemia patients did not harbor the characteristic malignant fusion genes found in leukemia cells.
• Leukemia-derived BMMSC showed no clonal malignant abnormalities, indicating biological normality.

Conclusions:

• Bone marrow mesenchymal stem cells from leukemia patients are biologically similar to those from healthy individuals.
• Leukemia-derived BMMSC lack malignant clonal abnormalities, suggesting they are safe for therapeutic use.
• BMMSC from leukemia patients represent a viable option for autologous stem cell transplantation, cell therapy, and gene therapy.